| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794752 | Ophthalmology Retina | 2017 | 12 Pages |
Abstract
RG7716 was well tolerated and exhibited an overall favorable safety profile, with evidence of improvements in BCVA and anatomic parameters. These data support further evaluation of RG7716 in phase II trials.
Keywords
IgGBCVAAMDiOpFcRnCNVTIE2CStChoroidal neovascularizationTEAEstandard of careimmunoglobulin Gbest-corrected visual acuitySingle dosemultiple doseage-related macular degenerationSOCcentral subfield thicknessadverse eventtreatment-emergent adverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressurePrincipal investigatorneonatal Fc receptor
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Usha MD, Clare MD, David MD, Peter MD, Mark MD, Karl MD, Adnan MD, Paul MD, Patrick PhD, Mylene PharmD, Paul PhD, Piotr MD, Jayashree MD, Anne PhD, Sandra MD, Sabine MD, Dietmar PhD,